Why Pfizer Is Still a Top Stock for 2021

Anirudh Shankar, The Motley Fool
·4 min read
Why Pfizer Is Still a Top Stock for 2021

Despite the successes of the past few months, including the release and rapid distribution of the company's COVID vaccine and impressive growth in its other therapeutics, Pfizer has fallen off its all-time high of $42.60 a share on Dec. 8 and into a very attractive valuation. Pfizer is one of the four iconic leaders of American pharmaceuticals, along with Johnson & Johnson, Merck, and Bristol Myers Squibb. Since its founding in 1849, Pfizer's 170-year-plus journey has included the development of several breakthrough drugs that have succeeded not just domestically, but internationally as well.